Boston, MA – November 7, 2023 – Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.
NETSseq platform identifies the astrocyte specific potassium channel KCNJ10 (kir4.1) as a target for the potential treatment of neurodegenerative diseases
Overview: Gene expression relevant to human disease pathology can be observed using Cerevance’s proprietary NETSseq platform. Data from this approach demonstrated that KCNJ10 is expressed in astrocytes from post-mortem brain tissue of Alzheimer’s and Parkinson’s disease donors and is increased in disease. Given that KCNJ10 is a central hub of many pathways significantly impacted by CNS diseases, including glutamate uptake, targeting this gene may present a novel approach to preventing neuronal hyperexcitability in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
Presenters: Clare Bender, Jenna Harvey
Session and Date and Time: Potassium Channels; November 15th, 8am – 12pm ET
Poster Number: C58
Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, prioritizing chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). Utilizing a large and growing collection of over 14,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
The company utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states. With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics that selectively modulate the discovered targets. These treatments are progressing through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline. CVN424 is a first-in-class non-dopamine therapy that shows promise in improving both motor and non-motor symptoms of Parkinson's disease and may also have disease-delaying effects. CVN766 is a potent antagonist of the orexin 1 receptor with high selectivity over the orexin 2 receptor which may benefit a variety of psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. CVN293 is a novel blocker of potassium efflux in glia, regulating the inflammasome in individuals living with ALS and Alzheimer's disease.
By leveraging its extensive collection of brain tissue samples, employing advanced technologies, and generating actionable data, Cerevance aims to transform the lives of patients affected by CNS diseases.
Johnna Simoes, firstname.lastname@example.org
Andrew Mielach, email@example.com, +1-646-876-5868